亚虹医药：APL-2401临床试验申请获批

Core Viewpoint - Aihong Pharmaceutical (688176) has received approval from the National Medical Products Administration for its clinical trial application of APL-2401, a first-class innovative drug targeting FGFR2/3-driven advanced solid tumors, marking a significant milestone in its development process [1] Group 1 - The clinical trial for APL-2401 (also known as ASN-8639 tablets) is approved to be conducted on patients with advanced solid tumors driven by FGFR2/3 [1] - APL-2401 is a globally developed innovative drug that meets international clinical trial technical standards [1] - The approval was granted within 22 working days, making it one of the first projects to receive approval under the new policy announced on September 12, 2025, which includes a "30-day channel" for innovative drug clinical trial reviews [1]